CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD)’s share price hit a new 52-week high on Monday . The stock traded as high as $11.00 and last traded at $10.66, with a volume of 148,000 shares changing hands. The stock had previously closed at $10.25.

Several equities analysts have recently weighed in on the company. Zacks Investment Research upgraded CoLucid Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 12th. Piper Jaffray Cos. restated an “overweight” rating and set a $21.00 price target on shares of CoLucid Pharmaceuticals in a report on Thursday.

The firm’s market cap is $163.46 million. The company’s 50 day moving average is $8.95 and its 200-day moving average is $7.30.

CoLucid Pharmaceuticals (NASDAQ:CLCD) last announced its quarterly earnings data on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by $0.22. Equities analysts predict that CoLucid Pharmaceuticals Inc. will post ($4.01) EPS for the current fiscal year.

In other news, major shareholder Domain Partners Vi, L.P. sold 153,028 shares of the company’s stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $8.45, for a total value of $1,293,086.60. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.